8. Balance Sheet Components (in thousands) | | | | | | | | | | June 30, | | December 31, | | | | 2026 | | 2025 | | Prepaid and Other Current Assets | | | | | | | | Interest receivable | | $ | 1,843 | | $ | 337 | | Prepaid research and development manufacturing expenses | | | 2,919 | | | 599 | | Prepaid insurance | | | 394 | | | 138 | | Other | | | 575 | | | 353 | | | | $ | 5,731 | | $ | 1,427 | | Property and Equipment | | | | | | | | Laboratory equipment | | $ | 2,996 | | $ | 2,646 | | Computer equipment and purchased software | | | 212 | | | 190 | | Leasehold improvements | | | 33 | | | 33 | | Construction in progress | | | 300 | | | — | | | | | 3,541 | | | 2,869 | | Less: accumulated depreciation and amortization | | | (2,711) | | | (2,649) | | | | $ | 830 | | $ | 220 | | Accrued and Other Liabilities | | | | | | | | Accrued clinical trial expense | | $ | 3,652 | | $ | 3,566 | | Accrued manufacturing expense | | | 3,032 | | | 1,812 | | Personnel related | | | 1,932 | | | 641 | | Accrued legal and accounting | | | 256 | | | 229 | | Other | | | 299 | | | 238 | | | | $ | 9,171 | | $ | 6,486 | |
During the three months ended June 30, 2026 and 2025, the Company recorded approximately $34,000 and $29,000 in depreciation expense, respectively, and during the six months ended June 30, 2026 and 2025, the Company recorded approximately $63,000 and $51,000 in depreciation expense, respectively.
|